BioDelivery (BDSI) Receives U.S. Patent for BEMA Products; Gets $15M Milestone
Tweet
Share
E-mailGet Alerts BDSI Hot Sheet
Join SI Premium – FREE
BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that the U.S. Patent and Trademark Office (USPTO) has formally awarded BDSI's patent No. 13/184306, "Transmucosal Delivery Devices with Enhanced Uptake," which extends the patent protection for BDSI's BioErodible MucoAdhesive (BEMA) products, BEMA Buprenorphine and BEMA Buprenorphine/Naloxone, by seven years to 2027. The USPTO had issued a Notice of Allowance to BDSI for this patent as previously disclosed in February of this year.
BDSI now confirms that the $15 million milestone associated with its licensing and development agreement with Endo Pharmaceuticals (Nasdaq: ENDP) for BEMA Buprenorphine is payable, bringing the total milestone payments received thus far to $45 million.
BDSI now confirms that the $15 million milestone associated with its licensing and development agreement with Endo Pharmaceuticals (Nasdaq: ENDP) for BEMA Buprenorphine is payable, bringing the total milestone payments received thus far to $45 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Home Depot expands executive roles, grants $500K in restricted stock
- Real and RE/MAX Holdings receive court approval for merger
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
